Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
Vitamin D supplementation may leads to lower maternal adverse events: severe postpartum haemorrhage compared with placebo or no intervention (low certainty).
It is very uncertain whether group A: amino acids changes adverse effects: suicidal thoughts Short‐term (events) compared with placebo (very low certainty).
The review found no eligible studies for this question.
Rituximab showed no clear difference in adverse effects ‐ infusion reactions: number of events compared with no rituximab (moderate certainty).
It is very uncertain whether transmural care changes adverse events: readmission to clinical rehabilitation compared with usual follow‐up care (very low certainty).
RISPERIDONE DEPOT showed no clear difference in adverse events: Any glucose‐related ‐ medium/long term compared with ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE) (low certainty).
Active cancer therapy combined with TCM showed no clear difference in adverse events ‐ neurotoxicity Diagnosed by clinicians compared with active cancer therapy (low certainty).
Propofol may leads to higher adverse event ‐ haemodynamic changes, number of events compared with sevoflurane (low certainty).
The intervention showed no clear difference in proportion of participants experiencing adverse events (low certainty).
Antiepileptic drugs showed no clear difference in any serious adverse event of treatment count of events compared with placebo or standard care (low certainty).
It is very uncertain whether prebiotics changes withdrawals due to adverse events (60 days to 6 months) compared with placebo (very low certainty).
Music therapy showed no clear difference in adverse events Any serious or non‐serious adverse event compared with placebo therapy or standard care (moderate certainty).
It is very uncertain whether botulinum toxin type A changes tolerability assessed by dropouts due to adverse events compared with anticholinergics (very low certainty).
Monthly pegloticase probably leads to higher number of participant withdrawals due to adverse events compared with placebo (moderate certainty).
Lesinurad 400 mg plus febuxostat CONTINUED showed no clear difference in number of participant withdrawals due to adverse events compared with lesinurad 200 mg plus febuxostat CONTINUED (low certainty).
Lesinurad 400 mg plus febuxostat CROSS showed no clear difference in number of participant withdrawals due to adverse events compared with lesinurad 200 mg plus febuxostat CROSS (low certainty).
Pegloticase every two weeks (biweekly) probably leads to higher number of participant withdrawals due to adverse events compared with placebo (moderate certainty).
Anti‐IL‐5 mAb (mepolizumab) showed no clear difference in adverse events ‐ nasopharyngitis, including sore throat compared with placebo (on top of topical steroids) (low certainty).
Anti‐IgE mAb (omalizumab) showed no clear difference in adverse events ‐ nasopharyngitis, including sore throat compared with placebo (on top of topical steroids) (low certainty).